Q2FY23 Financial Summary and Strategic Highlights

Q2 FY23 Revenue by portfolio and geography Worldwide U.S. Non-U.S. Developed Emerging Markets Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Cardiovascular 2,773 -1.9% 4.4% 1,424 3.7% 3.7% 802 -15.4% 0.2% 546 7.9% 13.4% Cardiac Rhythm & 1,431 -2.7% 3.5% Hearth Failure Structural Heart & 757 0.9% 8.1% Aortic Coronary & Peripheral Vascular 584 -3.6% 1.7% Medical Surgical 2,070 -10.0% -3.5% 905 -6.7% -6.7% 719 -14.5% 0.8% 446 -8.6% -4.7% Surgical Innovations 1,398 -6.6% 0.5% Respiratory, Gastrointestinal, & Renal 671 -16.3% -11.1% Neuroscience 2,186 2.3% 5.1% 1,512 8.5% 6.7% 382 -11.8% 4.4% 292 -5.5% -0.6% Cranial & Spinal 1,081 1.3% 4.6% Technologies Specialty Therapies 686 8.2% 9.1% Neuromodulation 419 -3.7% 0.5% Diabetes 556 -5.0% 3.1% 228 -12.6% -12.6% 254 -0.8% 16.0% 74 7.2% 13.0% Total Medtronic 7,585 -3.3% 2.2% 4,069 1.8% 1.2% 2,157 -13.0% 2.8% 1,359 -0.9% 3.9% 18 1Data has been intentionally rounded to the nearest million and, therefore, may not sum Investor Meetings | November 2022 Medtronic

View entire presentation